Cargando…
Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
pH-sensitive drug carriers that are sensitive to the acidic (pH = ~6.5) microenvironments of tumor tissues have been primarily used as effective drug/gene/siRNA/microRNA carriers for releasing their payloads to tumor cells/tissues. Resistance to various drugs has become a big hurdle in systemic chem...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081533/ https://www.ncbi.nlm.nih.gov/pubmed/27786239 http://dx.doi.org/10.1038/srep35223 |
_version_ | 1782462914826862592 |
---|---|
author | Reddy, Teegala Lakshminarayan Garikapati, Koteswara Rao Reddy, S. Gopal Reddy, B. V. Subba Yadav, J. S. Bhadra, Utpal Bhadra, Manika Pal |
author_facet | Reddy, Teegala Lakshminarayan Garikapati, Koteswara Rao Reddy, S. Gopal Reddy, B. V. Subba Yadav, J. S. Bhadra, Utpal Bhadra, Manika Pal |
author_sort | Reddy, Teegala Lakshminarayan |
collection | PubMed |
description | pH-sensitive drug carriers that are sensitive to the acidic (pH = ~6.5) microenvironments of tumor tissues have been primarily used as effective drug/gene/siRNA/microRNA carriers for releasing their payloads to tumor cells/tissues. Resistance to various drugs has become a big hurdle in systemic chemotherapy in cancer. Therefore delivery of chemotherapeutic agents and siRNA’s targeting anti apoptotic genes possess advantages to overcome the efflux pump mediated and anti apoptosis-related drug resistance. Here, we report the development of nanocarrier system prepared from kojic acid backbone-based cationic amphiphile containing endosomal pH-sensitive imidazole ring. This pH-sensitive liposomal nanocarrier effectively delivers anti-cancer drug (Paclitaxel; PTX) and siRNA (Bcl-2), and significantly inhibits cell proliferation and reduces tumor growth. Tumor inhibition response attributes to the synergistic effect of PTX potency and MDR reversing ability of Bcl-2 siRNA in the tumor supporting that kojic acid based liposomal pH-sensitive nanocarrier as efficient vehicle for systemic co-delivery of drugs and siRNA. |
format | Online Article Text |
id | pubmed-5081533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50815332016-10-31 Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma Reddy, Teegala Lakshminarayan Garikapati, Koteswara Rao Reddy, S. Gopal Reddy, B. V. Subba Yadav, J. S. Bhadra, Utpal Bhadra, Manika Pal Sci Rep Article pH-sensitive drug carriers that are sensitive to the acidic (pH = ~6.5) microenvironments of tumor tissues have been primarily used as effective drug/gene/siRNA/microRNA carriers for releasing their payloads to tumor cells/tissues. Resistance to various drugs has become a big hurdle in systemic chemotherapy in cancer. Therefore delivery of chemotherapeutic agents and siRNA’s targeting anti apoptotic genes possess advantages to overcome the efflux pump mediated and anti apoptosis-related drug resistance. Here, we report the development of nanocarrier system prepared from kojic acid backbone-based cationic amphiphile containing endosomal pH-sensitive imidazole ring. This pH-sensitive liposomal nanocarrier effectively delivers anti-cancer drug (Paclitaxel; PTX) and siRNA (Bcl-2), and significantly inhibits cell proliferation and reduces tumor growth. Tumor inhibition response attributes to the synergistic effect of PTX potency and MDR reversing ability of Bcl-2 siRNA in the tumor supporting that kojic acid based liposomal pH-sensitive nanocarrier as efficient vehicle for systemic co-delivery of drugs and siRNA. Nature Publishing Group 2016-10-27 /pmc/articles/PMC5081533/ /pubmed/27786239 http://dx.doi.org/10.1038/srep35223 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Reddy, Teegala Lakshminarayan Garikapati, Koteswara Rao Reddy, S. Gopal Reddy, B. V. Subba Yadav, J. S. Bhadra, Utpal Bhadra, Manika Pal Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
title | Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
title_full | Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
title_fullStr | Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
title_full_unstemmed | Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
title_short | Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
title_sort | simultaneous delivery of paclitaxel and bcl-2 sirna via ph-sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081533/ https://www.ncbi.nlm.nih.gov/pubmed/27786239 http://dx.doi.org/10.1038/srep35223 |
work_keys_str_mv | AT reddyteegalalakshminarayan simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma AT garikapatikoteswararao simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma AT reddysgopal simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma AT reddybvsubba simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma AT yadavjs simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma AT bhadrautpal simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma AT bhadramanikapal simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma |